Navigation Links
FDA Acting Chief Scientist Ostroff to Speak at the 2014 PDA/FDA Joint Regulatory Conference
Date:7/16/2014

BETHESDA, Md., July 16, 2014 /PRNewswire-USNewswire/ -- The Parenteral Drug Association (PDA) has confirmed  FDA's Stephen Ostroff, M.D., Acting Chief Scientist in the Office of the Commissioner will present "FDA's Views on Scientific Advances and their Impact on Manufacturing of the Future" on September 8, 2014 in at the opening plenary session of the 2014 PDA/FDA Joint Regulatory Conference in Washington, DC at the Renaissance Hotel. The Conference dates are September 8-10, 2014, and the theme is "Connecting Regulatory, Quality, Science & Compliance: Assuring Customer-Focused Outcomes throughout the Product Lifecycle"

"Participation of the Agency's Chief Scientist in a session on the future of manufacturing shows that the PDA/FDA Joint Regulatory Conference offers a wider range of information beyond just regulatory information," said PDA President Richard Johnson. "The agenda includes many presentations that are science and technology oriented, with a slant towards the Agency's regulatory role and activities in the various product areas."

Ostroff is responsible for leading and coordinating FDA's cross-cutting scientific and public health efforts. The Office of the Chief Scientist works closely with FDA's product centers, providing strategic leadership and support for FDA's regulatory science and innovation initiatives. 

These initiatives include the Advancing Regulatory Science Initiative, the Critical Path Initiative, scientific professional development, scientific integrity, and the Medical Countermeasure initiative (MCMi).

Ostroff joined FDA in 2013 as Chief Medical Officer in the Center for Food Safety and Applied Nutrition and Senior Public Health Advisor to FDA's Office of Foods and Veterinary Medicine. Prior to that he served as Deputy Director of National Center for Infectious Diseases at the Centers for Disease Control and Prevention (CDC), where he was also Acting Director of CDC's Select Agent Program. He retired from the Commissioned Corps of the U.S. Public Health Service at the rank of Rear Admiral (Assistant Surgeon General). 

Ostroff joins 27 other confirmed FDA officials speaking at the conference, including Center for Drug Evaluation and Research Director Janet Woodcock, M.D.

Dr. Janet Woodcock is confirmed to provide remarks addressing "The Cost of Poor Quality" on Tuesday, September 9, 2014

Allergy Laboratories' Susan Schniepp and FDA/Office of Regulatory Affair's (ORA) Monica Caphart are co-chairing this event.  Other confirmed senior FDA officials include: CBER's Dr. Karen Midthun and Mary Malarkey; CVM's Dr. Bernadette Dunham and Dr. Martine Hartogensis; CDER's Ilisa Bernstein; CDRH's Steve Silverman; ORA's Dr. Steven Solomon and Douglas Stearn as well as a host of senior staff scientists and pharmaceutical manufacturing scientists.

To review the entire program and register, please see: http://www.pda.org/global-event-calendar/event-detail/2014-pda-fda-joint-regulatory-conference.

The Conference is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

About PDA – Connecting People, Science and Regulation®

The Parenteral Drug Association (PDA) is the leading global provider of science, technology and regulatory information and education for the pharmaceutical and biopharmaceutical community. Founded in 1946 as a nonprofit organization, PDA is committed to developing scientifically sound, practical technical information and resources to advance science and regulation through the expertise of its more than 9,500 members worldwide. Go to http://www.pda.org/footer/about-pda to learn more.

Media Inquiries: Walt Morris, 301-656-5900, x. 148; morris@pda.org

Logo - http://photos.prnewswire.com/prnh/20130226/DC66667LOGO


'/>"/>
SOURCE Parenteral Drug Association
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
2. Purdue Pharma L.P. Comments on FDA Announcement on REMS for Extended-Release and Long-Acting Opioid Analgesics
3. Biodel Awarded NIH Grant to Develop Concentrated Ultra-Rapid-Acting Insulin Formulations for Use in Artificial Pancreas
4. Vesta Inc. Opens Frankfurt Office to Increase Service to Their Growing Medical Device Contracting Business Overseas
5. Technologies Impacting the Future of Healthcare
6. Biodel Announces Phase 2 Clinical Trial Initiation Of Ultra-Rapid-Acting Insulin Candidate BIOD-123
7. Study Published In Contraception Evaluates Medical Expenditures For Unintended Pregnancies And Potential Cost Impact Of Increased Use Of Long-Acting Reversible Contraception
8. NKTR-192, A New Short-Acting Mu-Opioid Analgesic Molecule, Achieves Desired Pharmacokinetic Profile in First Phase 1a Clinical Study
9. Polymers in Medical Devices: Opportunities Arising and Trends Impacting the Market
10. PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
11. Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... LOVELAND, Colo. , July 26, 2017 ... Tristan Guttridge and the Bimini SharkLab to custom design the ... diagnostic images of sharks in their native habitat. In ... for Discovery Channel,s Shark Week, Dr. Guttridge approached ... to take pregnancy diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
(Date:7/25/2017)... CAMBRIDGE, Massachusetts , July 25, 2017 /PRNewswire/ ... drugs to treat rare nervous system diseases, has concluded a ... and market the drug SOM0226 against transthyretin amyloidosis (ATTR). Before ... promising results in a Phase 2 study conducted in ... in the United States ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... August 17, 2017 , ... Tanya Atagi, MD, is excited to announce ... Atagi Plastic Surgery and Skin Aesthetics. , To tighten skin on the face, ... ultrasound energy. Smoother, younger-looking skin is revealed on all other areas of the body ...
(Date:8/17/2017)... CO (PRWEB) , ... August 17, 2017 , ... ... Moral Injury: The Journey to Healing Through Forgiveness ($15.99, paperback, 9781498497626; $7.99, ... (war) trauma, to encourage inner healing of memories and achieve forgiveness, through a ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Pot Valet is ... service growing to every city in the state, and soon, every state in the ... their need to visit a cannabis dispensary altogether. , According to Pot ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Centrifugation is more ... in the laboratory that we can no longer do without. And just like a ... of your device. , In this webinar, attendees will learn about the most important ...
(Date:8/17/2017)... Seattle, WA and Lighthouse Point, FL (PRWEB) , ... ... ... Seattle-based healthcare technology firm and Cancer Center Business Development Group, a Florida-based oncology ... that examined patient care data to quantify the dollar amount of attributable savings ...
Breaking Medicine News(10 mins):